Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Por: Jacob, S, Muppidi, S, Guidon, A, Guptill, J, Hehir, M, Howard, JF, Illag, I, Mantegazza, R, Murai, H, Utsugisawa, K, Vissing, J, Wiendl, H, Nowak, RJ, Int MG COVID-19 Working Grp

---

Publicada: 15 may 2020

---

---

Filiaciones:
Jacob, S:
 Univ Hosp, Inst Immunol & Immunotherapy, Dept Neurol, Birmingham B15 2TH, W Midlands, England

Muppidi, S:
 Stanford Neurosci Hlth Ctr, Dept Neurol, Palo Alto, CA 94304 USA

Guidon, A:
 Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA

Guptill, J:
 Duke Univ, Dept Neurol, Med Ctr, Durham, NC 27710 USA

Hehir, M:
 Univ Vermont, Dept Neurol, Med Ctr, Burlington, VT 05401 USA

Howard, JF:
 Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA

Illag, I:
 Hosp Santa Creu & Sant Pau, Unitat Patol Neuromuscular, Servei Neurol, Catedrat Neurol UAB, C Pare Claret 167, Barcelona 08025, Spain

Mantegazza, R:
 Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Via Celoria 11, I-20133 Milan, Italy

Murai, H:
 Int Univ Hlth & Welf, Sch Med, Dept Neurol, Narita, Japan

Utsugisawa, K:
 Hanamaki Gen Hosp, Dept Neurol, Hanamaki, Japan

Vissing, J:
 Univ Copenhagen, Rigshosp 2082, Dept Neurol, DK-2100 Copenhagen, Denmark

Wiendl, H:
 Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany

Nowak, RJ:
 Yale Univ, Dept Neurol, Sch Med, New Haven, CT 06520 USA